Molecular Templates to Present at 2013 BIO International Convention

Molecular Templates to Present at 2013 BIO International Convention

<0> Molecular Templates, Inc.Jason Kim, 512-639-0206 </0>

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapies, announced today that it will present at the upcoming 2013 BIO International Convention in Chicago, IL, on Tuesday, April 23, 2013.

Eric Poma, CEO and CSO, will present an overview of the company’s ongoing pre-clinical programs utilizing its novel platform for developing targeted biologics with unique biological properties.

“We look forward to sharing the company’s unique biologic platform for drug development with the BIO International audience,” said Eric Poma, CEO and CSO, Molecular Templates. “Our technology represents a new class of targeted therapeutics with predictable pharmacokinetics and unique functionalities. As we advance our candidates forward, we are excited about leveraging the broad utility of our technology for a variety of cancer types and settings.”

Event: 2013 BIO International ConventionDate: Tuesday, April 23, 2013Time: 9:45 am (Central Time)Location: Chicago Blackhawks Room; McCormick Place Convention Center; Chicago

About Molecular Templates

Molecular Templates is a venture-backed biopharmaceutical company focused on the discovery and development of a new class of targeted biologic therapeutics. The company is pursuing development of various leads across a wide range of cancers.

For more information, please visit .

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.